<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04275518</url>
  </required_header>
  <id_info>
    <org_study_id>APG115AC101</org_study_id>
    <nct_id>NCT04275518</nct_id>
  </id_info>
  <brief_title>A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.</brief_title>
  <official_title>A Phase Ib Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of APG-115 as a Single Agent or in Combination With Azacitidine or Cytarabine in Patients With Relapse/Refractory AML and Relapsed/Progressed High/Very High Risk MDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascentage Pharma Group Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Suzhou Yasheng Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ascentage Pharma Group Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute myeloid leukemia is a malignant disorder characterized by the rapid, uncontrolled&#xD;
      proliferation of malignant clonal hematopoietic stem cells that accumulate as immature,&#xD;
      undifferentiated cells (blasts) in the bone marrow and circulation.&#xD;
&#xD;
      APG-115 is a potent and orally active small-molecule MDM2 inhibitor, it binds to MDM2 protein&#xD;
      and shows potent cell growth inhibitory activity in vitro with low nanomolar potencies in a&#xD;
      subset of human cancer cell lines. APG-115 has demonstrated its strong antitumor activities&#xD;
      with either daily or less frequent dosing-schedules in the acute leukemia xenograft models.&#xD;
&#xD;
      This is a phase 1b, open-label, three-stages study that will initially evaluate the safety&#xD;
      and PK/PD profile of APG-115 as a single agent, followed by a combination of APG-115 +&#xD;
      azacytidine or cytarabine in R/R AML or MDS subjects.&#xD;
&#xD;
      Patients will continue treatment for maximally 6 cycles or until progression of disease or&#xD;
      unacceptable toxicity is observed or administrative discontinuation whichever occurs first.&#xD;
      Patients who continue to be benefit after 6 cycles' treatment will receive additional cycles&#xD;
      of treatment until progression of disease, unacceptable toxicity is observed or&#xD;
      administrative discontinuation. (As long as it is proven safe).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stage 1: This will be a 3+3 dose escalation to determine the DLTs and MTD/RP2D of APG-115&#xD;
      given according to the different dose levels once daily from Days 1 to 7 every 28 days.&#xD;
&#xD;
      Stage 2: After stage 1 of APG-115 single agent dose escalation first cycle is completed,&#xD;
      stage 2 can be initiated with the combination regimen. This will be a 3+3 dose escalation to&#xD;
      determine the MTD/RP2D and DLTs of APG-115 + AZA(arm A)/Cytarabine (arm B)combination.&#xD;
&#xD;
      Stage 3: dose expansion of the combination regimes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Anticipated">August 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLT)</measure>
    <time_frame>From day 1 to the end of cycle 1 (each cycle is 28 days).</time_frame>
    <description>DLT will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE, version 5) by organ system. DLT will be defined as clinically significant drug-related adverse events during the Cycle one.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Evaluated for response by the end of cycle 1 and cycle 2, and then 2 months thereafter till complete 6 cycles treatment or 1 month after last dose (each cycle is 28 days).</time_frame>
    <description>ORR is defined by CR + CRi+ PR (according to IWG AML（2003）and IWG MDS（2006）criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Measured up to 6 months after the last subject has received treatment.</time_frame>
    <description>From date of treatment start until the date of death due to any cause or date of termination of the study, whichever came first. Termination of the Study: The last subject has completed at least 6 cycle's treatment or the subject discontinues treatment for any reason.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Myelodysplastic Syndromes (MDS)</condition>
  <arm_group>
    <arm_group_label>APG-115/APG-115+Cytarabine in Relapse/Refractory AML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>APG-115/APG-115+Aza in relapsed/progressed high risk MDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APG-115</intervention_name>
    <description>APG-115 orally once daily from Days 1 to 7 every 28 days.</description>
    <arm_group_label>APG-115/APG-115+Aza in relapsed/progressed high risk MDS</arm_group_label>
    <arm_group_label>APG-115/APG-115+Cytarabine in Relapse/Refractory AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>75 mg/m^2 SC QD on Days 1- 7 (28-day cycle)</description>
    <arm_group_label>APG-115/APG-115+Aza in relapsed/progressed high risk MDS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>1g/m^2 IV QD on Days 3-7 (28-day cycle)</description>
    <arm_group_label>APG-115/APG-115+Cytarabine in Relapse/Refractory AML</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a diagnosis of histologically confirmed relapsed or refractory (R/R)&#xD;
             acute myeloid leukemia by WHO classification or relapsed/progressed high/very high&#xD;
             risk MDS (score≥4.5) according to IPSS-R risk stratification&#xD;
&#xD;
          2. Age &gt;/= 18 years.&#xD;
&#xD;
          3. Adequate organ function&#xD;
&#xD;
          4. Subject must have a projected life expectancy of at least 12 weeks.&#xD;
&#xD;
          5. ECOG performance status of 0-1.&#xD;
&#xD;
          6. Patient must have the ability to understand the requirements of the study and signed&#xD;
             informed consent. A signed informed consent by the patient or his legally authorized&#xD;
             representative is required prior to their enrollment on the protocol.&#xD;
&#xD;
          7. Subject has a white blood cell count&lt; 50 × 109/L. Note: Hydroxyurea is permitted to&#xD;
             meet this criterion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has acute promyelocytic leukemia.&#xD;
&#xD;
          2. Patients must not have had leukemia biotherapy 12 weeks prior to starting&#xD;
             investigational drug, or less than 5 half-lives small molecular targeted drug therapy,&#xD;
             or 28 days any anti-cancer therapy (whichever is longer)&#xD;
&#xD;
          3. Uncontrolled intercurrent illness including, but not limited to active uncontrolled&#xD;
             infection, symptomatic congestive heart failure (NYHA Class III or IV), unstable&#xD;
             angina pectoris, clinically significant cardiac arrhythmia, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements.&#xD;
&#xD;
          4. Active infection requiring systemic antibiotic/antifungal medication, known clinically&#xD;
             active hepatitis B or C, or HIV infection.&#xD;
&#xD;
          5. Participants who have received allogeneic HSCT, or autologous HSCT within 12 months.&#xD;
&#xD;
          6. Patients with active, uncontrolled CNS leukemia will not be eligible.&#xD;
&#xD;
          7. Any prior systemic MDM2-p53 inhibitor treatment&#xD;
&#xD;
          8. Any other condition or circumstance that would, in the opinion of the investigator,&#xD;
             make the patient unsuitable for participation in the study.&#xD;
&#xD;
          9. Subject has a history of other malignancies within 5 years prior to study entry, with&#xD;
             the exception of:&#xD;
&#xD;
               -  Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of&#xD;
                  breast;&#xD;
&#xD;
               -  Basal cell carcinoma of the skin or localized squamous cell carcinoma of the&#xD;
                  skin;&#xD;
&#xD;
               -  Previous malignancy confined and surgically resected (or treated with other&#xD;
                  modalities) with curative intention: requires discussion with sponsor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianxiang Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood Diseases Hospital Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junyuan Qi, M.D.</last_name>
    <phone>+86-18622662361</phone>
    <email>qi_jy@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bo Jiang, M.D.</last_name>
    <phone>+86-22-23909067</phone>
    <email>jianbo044@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangzhou panyu central hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuqin Cheng, Master</last_name>
    </contact>
    <contact_backup>
      <last_name>Hui Yang Professor</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Zhang, Master</last_name>
    </contact>
    <contact_backup>
      <last_name>Chongyuan Xu Professor</last_name>
      <phone>86-020-62786845</phone>
      <email>nfyygcp@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Henan Provincial Oncology Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xudong Wei, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Hospital medical college Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiubo Li, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuling Zhou, M.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Jianying Huang Director</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qun He, Master</last_name>
    </contact>
    <contact_backup>
      <last_name>Qun Qin, M.D.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The First affiliated hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaowen Tang, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sujun Gao, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiao Tong University school of medicine Ruijing Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junmin Li Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth people's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunkang Chang Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blood Diseases Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianxiang Wang, MD</last_name>
      <phone>+86 22-23909120</phone>
      <email>wangjx@ihcams.ac.cn</email>
    </contact>
    <contact_backup>
      <last_name>Junyuan Qi, MD</last_name>
      <phone>+86 18622662361</phone>
      <email>qi_jy@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>APG-115</keyword>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

